Lineage Cell Therapeutics (LCTX) Long-Term Deferred Tax (2013 - 2026)

Lineage Cell Therapeutics' Long-Term Deferred Tax history runs 10 years deep, the most recent figure standing at $5.8 million for Q1 2026.

• On a quarterly basis, Long-Term Deferred Tax changed N/A year-over-year to $5.8 million in Q1 2026; TTM through Mar 2026 was $5.8 million, a N/A change from a year earlier, with the FY2025 full-year figure at $5.8 million, up 2024.54% from the prior year.
• Long-Term Deferred Tax was little changed at $5.8 million in Q1 2026 per LCTX's latest filing, from $5.8 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $5.8 million in Q4 2025 and bottomed at $273000.0 in Q4 2024.
• The 3-year median for Long-Term Deferred Tax is $5.8 million (2025), against an average of $4.0 million.
• Biggest YoY gain for Long-Term Deferred Tax was 2024.54% in 2025; the steepest drop was 2024.54% in 2025.
• Year by year, Long-Term Deferred Tax stood at $273000.0 in 2024, then surged by 2024.54% to $5.8 million in 2025, then changed by 0.0% to $5.8 million in 2026.
• Per Business Quant, the three latest LCTX Long-Term Deferred Tax figures stand at $5.8 million (Q1 2026), $5.8 million (Q4 2025), and $273000.0 (Q4 2024).